Century Therapeutics, Inc. announced its financial results for the year ended December 31, 2025, highlighting a significant increase in collaboration revenue to $109.2 million from $6.6 million in 2024. The company also reported a net loss of $9.6 million, a substantial improvement from $126.6 million in the previous year. Key developments include advancements in their CNTY-813 and CNTY-308 programs, with IND submissions planned for 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.